64th ASH Annual Meeting and Exposition: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Relapsed and/or Refractory Myeloma (RRMM)

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological Oral and Poster Abstracts
Oral

Research, clinical trials, Biological therapies, Antibody Therapy, adult, Translational Research, epidemiology, Clinical Practice (Health Services and Quality), Bispecific Antibody Therapy, Clinical Research, health outcomes research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, hematopoiesis, health disparities research, Diseases, Immunotherapy, Therapies, therapy sequence, Lymphoid Malignancies, Adverse Events, Infusion, Biological Processes, Monoclonal Antibody Therapy, Study Population, Human, Minimal Residual Disease

R02-R05 (Ernest N. Morial Convention Center)

Moderators:

Nisha S. Joseph, MD, and Adriana Rossi, MD, MSc, Mount Sinai Hospital

Disclosures:

No relevant conflicts of interest to declare.

2:00 PM

247

Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies

Paul G. Richardson, MD^1,2, Aurore Perrot, MD, PhD³^*, Jesús San-Miguel, MD, PhD⁴, Meral Beksac, MD⁵, Ivan Spicka, MD, Prof, PhD⁶^*, Xavier Leleu, MD, PhD⁷, Fredrik Schjesvold, MD, PhD⁸, Philippe Moreau, MD⁹^*, Meletios A. Dimopoulos, MD¹⁰, Jeffrey SY Huang, M.D., Ph.D.¹¹^*, Jiri Minarik, MD¹², Michele Cavo, MD¹³^*, H. Miles Prince, MD, FRACP, FRCPA¹⁴, Sandrine Macé, PhD¹⁵^*, Laure Malinge¹⁶^*, Franck Dubin, PharmD¹⁷^*, Mony Morisse, MD, MSc¹⁸^* and Kenneth C. Anderson, MD¹⁹

¹Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
³Department of Hematology, Toulouse University Institute of Cancer, Toulouse, France
⁴Clínica Universidad de Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain
⁵Department of Hematology, Ankara University, Ankara, Turkey
⁶General Faculty Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
⁷Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers, France
⁸Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway, and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway
⁹Hematology Department, University Hospital Hôtel-Dieu, Nantes, France
¹⁰Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
¹¹Department of Hematology, National Taiwan University Hospital, Taipei, Taiwan
¹²Department of Hemato-oncology, Faculty Hospital and Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
¹³Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy
¹⁴Immunology and Molecular Oncology, Epworth Healthcare, University of Melbourne, Melbourne, VIC, Australia
¹⁵Sanofi, Vitry-Sur-Seine, France
¹⁶Sanofi on behalf of Aixial, Boulogne-Billancourt, France
¹⁷Sanofi, Vitry-sur-Seine, France
¹⁸Sanofi, Cambridge
¹⁹Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School,, Boston, MA

2:15 PM

248

No Evidence of BCMA Expression Loss or Systemic Immune Impairment after Treatment with the BCMA-Targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Daniel E. Lowther, PhD¹^*, E. Andres Houseman, ScD²^*, Gang Han, PhD²^*, Eleni Kleanthous, MSc¹^*, Dawson Knoblock, PhD²^*, Xiangdong Zhou, PhD²^*, Shreyan Banerjee, MSc³^*, Sagar Patel, MSc²^* and David Figueroa, BA²^*

¹GSK, Stevenage, United Kingdom
²GSK, Upper Providence, PA
³GSK, Bengaluru, India

2:30 PM

249

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Santiago Thibaud, MD¹, Md. Babu Mia, PhD¹^*, Oliver Van Oekelen, MD, PhD², Tarek H. Mouhieddine, MD¹, Christoph Schaniel, PhD¹^*, Yogita Ghodke-Puranik, PhD¹^*, Adolfo Aleman, MPA¹^*, Bhaskar Upadhyaya, PhD¹^*, Guido Lancman, MD, MSc¹, Alessandro Lagana, PhD¹, Shambavi Richard, MD¹, Adriana Rossi, MD, MSc¹, Ajai Chari, MD¹^*, Larysa Sanchez, MD¹^*, Cesar Rodriguez, MD¹^*, Hearn J. Cho, MD, PhD¹, Joshua Richter, MD¹, Ronald Hoffman, MD¹, Sundar Jagannath¹ and Samir Parekh, MD¹

¹Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
²Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY

2:45 PM

250

Clinical Outcomes and Salvage Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy

Kevin R Reyes, BS¹^*, Yen-Chun Liu, BS²^*, Chiung-Yu Huang, PhD³^*, Rahul Banerjee, MD⁴, Thomas Martin, MD⁵, Nina Shah, MD⁶, Sandy W. Wong, MD⁷, Jeffrey L. Wolf, MD⁷, Shagun Arora, MD⁷ and Alfred Chung, MD⁷

¹School of Medicine, University of California, San Francisco, Millbrae, CA
²Department of Statistical Science, Duke University, Durham, NC
³Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA
⁴Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA
⁵UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
⁶Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA
⁷Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA

3:00 PM

251

Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma

Noriko Nishimura, MD, PhD¹^*, Samantha Brown, MS²^*, Sean M. Devlin, PhD³^*, Parastoo B. Dahi, MD^4,5, Heather Landau, MD^4,6, Oscar B Lahoud, MD⁶, Michael Scordo, MD^4,7, Gunjan L. Shah, MD^4,8^*, Hani Hassoun, MD⁹, Malin Hultcrantz, MD, PhD⁹, Neha Korde, MD⁹, Alexander M Lesokhin, MD^5,10, Sham Mailankody, MBBS ⁵, Urvi A Shah, MD⁹, Carlyn Tan, MD⁹, Saad Usmani, MD¹¹, Sergio A. Giralt, MD, FACP, FASTCT^4,12^*, David J. Chung, MD, PhD^4,6, Gaurav Gupta¹³^*, Elena Maryamchik¹³^*, Evangelos Ntrivalas¹⁴^* and Mikhail Roshal, MD¹⁵

¹the Sloan Kettering Institute for Cancer Research, New York, NY
²Department of Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
³Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Department of Medicine, Weill Cornell Medical College, New York, NY
⁵Memorial Sloan Kettering Cancer Center, New York, NY
⁶Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
⁷Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center/New York, New York, NY
⁸Department of Medicine, Adult Bone Marrow Transplant Service, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁹Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁰Weill Cornell Medical College, New York, NY
¹¹Levine Cancer Institute, New York, NY
¹²Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY
¹³Transfusion Medicine and Cell Therapy, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York
¹⁴Cellular Immunology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York
¹⁵Department of Pathology and Laboratory Medicine, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY

3:15 PM

252

Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy

Lauren C. Peres, PhD, MPH¹^*, Laura B. Oswald, PhD²^*, Christen Dillard, MD³, Gabriel De Avila, BS⁴^*, Taiga Nishihori, MD⁵, Brandon J. Blue, MD⁶, Ciara L. Freeman, MSc, FRCPath, MBBChir, MRCP⁴, Frederick L. Locke, MD⁷, Melissa Alsina, MD**⁸, Omar Alexis Castaneda Puglianini, MD⁹, Leyla O. Shune, MD¹⁰, Douglas W. Sborov, MD¹¹, Charlotte B Wagner, PharmD¹²^*, Danai Dima, MD¹³, Hamza Hashmi, MD¹⁴, James Davis, PharmD¹⁴^*, M. Hakan Kocoglu, MD¹⁵, Shebli Atrash, MD¹⁶, Gary Simmons, DO¹⁷, Nilesh Kalariya³^*, Christopher J. Ferreri, MD³, Aishwarya Sannareddy, MBBS¹⁸^*, Aimaz Afrough, MD¹⁹, Peter M. Voorhees, MD²⁰, Jack Khouri, MD²¹, Joseph P. McGuirk, DO²², Surbhi Sidana, MD²³, Doris K. Hansen, MD⁵ and Krina Patel, MD, MSc²⁴

¹H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
²Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
³The University of Texas MD Anderson Cancer Center, Houston, TX
⁴Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
⁵Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL
⁶Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
⁷Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁸Moffitt Cancer Center, Tampa, FL
⁹Department of Blood & Marrow Transplant and Cellular Immunotherapy, Vcu-Massey Cancer Center, Tampa, FL
¹⁰The University of Kansas Medical Center, Kansas City, KS
¹¹Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
¹²University of Utah Huntsman Cancer Institute, Salt Lake City, UT
¹³Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
¹⁴Department of Hematology/Medical Oncology, Medical University of South Carolina, Charleston, SC
¹⁵University of Maryland, Baltimore, MD
¹⁶Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
¹⁷Virginia Commonwealth University Massey Cancer Center, Richmond, VA
¹⁸Division of Hematology and Oncology, UT Southwestern Medical Center, Dallas, TX
¹⁹Division of Hematologic Malignancies and Cellular Therapy, Dept of Internal Medicine, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
²⁰Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Center, Charlotte, NC
²¹Department of Hematology and Medical Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
²²Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS
²³Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA
²⁴Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

652A.O1.6 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Relapsed and/or Refractory Myeloma (RRMM)